Last reviewed · How we verify
PHOSPHATIDYLCHOLINE
At a glance
| Generic name | PHOSPHATIDYLCHOLINE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease (EARLY_PHASE1)
- A Real World Study of Polyene Phosphatidylcholine Injection for the Prevention and Treatment of DILI in Patients With Malignant Hematological Diseases
- Child Health, Agriculture and Integrated Nutrition (NA)
- Temporary Inactivation of Strong Muscle Sensation to Improve Rehabilitation Interventions in SCI (PHASE1)
- Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults (PHASE1)
- Acute Effects of Alpha-glycerylphosphorylcholine (A-GPC) on Lower Body Muscular Performance. (NA)
- Resistance Training and Post Workout Protein to Improve Body Composition During Neoadjuvant Chemotherapy for Breast Cancer (NA)
- Evaluate the Efficacy and Safety of AYP-101 for the Reduction of Submental Fat in Chin Area (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PHOSPHATIDYLCHOLINE CI brief — competitive landscape report
- PHOSPHATIDYLCHOLINE updates RSS · CI watch RSS